ClinicalTrials.gg
RecruitingNCT07154719GRAMSUpdated Aug 27, 2026

GLP-1R Actions on Muscle and the Skeleton

A Phase 4 interventional study of Tirzepatide and Lifestyle toolkit in Musculoskeletal Abnormalities, Obesity and Sarcopenic Obesity, sponsored by Pennington Biomedical Research Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Pennington Biomedical Research Center · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies testing tirzepatide in Obesity — 62 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Planned enrollment
65th of 106
50 · median 69
Started
2025
with 33 others
Phase 4
30 of 106
21 open now
Primary completion
2027-02
later than 19 of 78 live
Registered
62nd of 106
by date

Among the 106 studies testing tirzepatide in Obesity, this one is the 65th largest by planned enrollment, is one of 34 that started in 2025, is one of 30 in phase 4, reaches primary completion later than 19 of the 78 other live ones, and was the 62nd registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

62 of the 106 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

57 more — sign in →

By country, each count listing its studies:

All 62 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.

Read the detailed description

Obesity and type 2 diabetes remain at epidemic proportions in our country particularly in vulnerable populations such as elderly, and minority patients. Over the last 20 years, the use of incretin-based agents (Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) and Glucose dependent insulinotrophic polypeptide (GIP) to treat these disorders has offered unprecedented advances based on significant weight loss and reduction in major cardiovascular endpoints. Whilst weight loss provides a vital aspect for addressing obesity and type 2 diabetes, there are concerns associated with the quality of weight reduction.

The impact of losing weight on the musculoskeletal system has garnered recent attention in the lay press. Reported high-impact studies have reported excessive loss of skeletal muscle using GLP-1 RAs. The data regarding combined therapies (GLP-1 RA and GIP) suggested smaller loses. This preliminary data is based on using a surrogate marker (fat-free mass) determined by dual energy x-ray absorptiometry (DXA).

Recent reviews evaluating the impact that incretin-based agents have on fat-free-mass were found to be inconclusive based on high variability and multiple confounding factors. Assessing the impact that these agents have on the musculoskeletal system is now an important endeavor. (Aim 1-2) Diet-induced weight loss is also associated with bone loss, although little attention has focused on this potentially problematic outcome. In the CALERIE study, modest caloric restriction (15%) over two years led to weight loss and a 2% reduction in hip bone mineral density (BMD) among normal weight individuals. The mechanisms of weight loss-induced bone loss are unclear, although a drop in fat-free mass (which is composed of skeletal muscle, organs, water and connective tissues) principally muscle, such as occurs with the GLP1RAs, may predispose to injury, disability and bone loss. Another possibility is a mechanical form of skeletal adaptation to lower lean mass, through myokine mediated bone remodeling. However, significant trabecular bone loss in a non-weight bearing skeletal site occurs in mice as the investigators have shown in the mandible, from a 30% CR diet (Liu, personal communication). As such gravitational unloading due to weight loss is not solely responsible for deleterious skeletal changes. Despite the dramatic weight and lean mass loss from the GLP1 RAs, few clinical trials have focused on loss of muscle mass and fewer on any skeletal changes. In those that did, the results suggest equipoise for skeletal changes. There are no data on the skeletal effects from tirzepatide which can drive up to 25% weight loss. (Aim 1c) Also, it is unknown whether the addition of dietary modifications and resistance-based exercises impacts skeletal adaptation, muscle mass and bone loss. (Aim 2) Furthermore, there are inconsistent data in non-Hispanic Blacks with the GLP1 RAs because trial participation in under-represented populations has been poor. Hence, there is a major knowledge gap in our understanding the impact that a mixed GIP and GLP1RA, tirzepatide affects muscle and bone mass, particularly among underserved populations.

The wide-spread usage of GLP-1 related agents has not required formal recommendations regarding the use of exercises, specifically resistance-based exercises, or dietary protein optimization to address the potential for loss of fat-free mass or bone mineral density that has been suggested in studies evaluating body composition and bone density in subjects using these compounds. While the data for using such lifestyle interventions with diet and bariatric surgery have confirmed benefits in reducing loss of fat-free mass, the investigators know of only 1 published report using GLP-1 agents and exercise: Lundgren et al. found that in subjects using additional resistance-based exercise had a more favorable impact on sparing fat-free mass.

Additional gaps in our understanding remain despite the growing use and popularity of these agents. Additionally, patients with obesity and type 2 diabetes tend to develop ectopic fat within muscle (myosteatosis) that is not measured as part of fat free mass by DXA. It is posited that the major depot for acute loss of skeletal muscle from rapid weight loss may be from this portion of poor-quality lipid-rich tissue quelling major concerns. (Aim 2b) Aim 3, an explorative outcome, the investigators will determine if tirzepatide causes bone loss by measuring bone formation (P1NP) and bone resorption markers (NTx), if imbalanced skeletal remodeling is related to the change in total lean mass, muscle mass through reduced myokine (i.e., irisin) release, skeletal adaptation to weight change or another endocrine mechanism. Using a team science approach, the investigators will combine the expertise in metabolism and body composition of the PBRC group with skeletal expertise from MaineHealth to provide key insights into musculoskeletal effects from tirzepatide, a relatively new but often sought after drug for weight loss and type 2 diabetes. This supplement could also shed light on newer mechanisms of weight loss-induced bone loss and set the stage for a larger clinical trial.

03

Conditions studied

  • Musculoskeletal Abnormalities
  • Obesity
  • Sarcopenic Obesity
  • Osteoporosis
  • Drug Effect

Keywords

  • GLP-1 agonists
  • Obesity treatments
  • Muscleskeletal loss
  • Tirzepatide
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will have a between 30kg/m2

    • 40kg/m2 (inclusive)
  • Be between 18 and 50 years of age (inclusive).
  • Non-Hispanic Black males and females will be enrolled at PBRC.
  • Rural males and females will be enrolled at MaineHealth.
  • Female subjects will be premenopausal.
  • Females have had their last menstrual period less than 60 days before screening.
  • Females have the absence of menopausal-associated vasomotor symptoms.
  • All subjects must be able to use Lifestyle Toolkit as prescribed for intervention arm.

Exclusion criteria

Exclusion Criteria:

- Males and females over the age of 50 years of age

  • Menopausal females.
  • Subjects on systemic or other agents known to increase loss of muscle and bone mass.
  • Subjects who are on medications that increase or decrease weight status.
  • Subjects having to tirzepatide in the package insert.
  • Subjects with a history of other than non-melanoma skin cancer
  • Subjects with known osteoporosis or are on osteoporosis therapies (gonadal hormones or hormone antagonists).
  • Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.
  • Subjects with a hematologic abnormality, kidney disease, liver disease, or diabetes.
  • Females of who do not agree to using an effective method of during the study. Medically acceptable methods include oral contraceptive medication, an intrauterine device (IUD), an implantable contraceptive (such as Implanon), or a barrier method (such as condom or diaphragm with spermicide).

Injectable contraceptives such as Depo-Provera are a cause for exclusion in that they can cause bone loss.

Abstinence is acceptable, as is sexual activity exclusively with same sex partners.

Fertility Appreciation Based Methods (natural family planning) are also acceptable forms of addressing childbearing potential in all subjects. A urine pregnancy test (UPT) will be performed on all females of childbearing potential at the screening visit, 3 and 6 months.

  • Unable to follow Lifestyle Toolkit as prescribed for intervention arm.
  • Patient Health Questionnaire-9 (PHQ-9) Score equal to or greater than 15 (clinical depression).
  • Adults who are unable to consent.
  • Individuals who are not yet adults (infants, children and teenagers).
  • Pregnant females.
  • Incarcerated individuals.
  • Contraindication to MRI - including but not limited to non-removable metallic or electronic implants, claustrophobia or other fear of confinement, inability to tolerate loud scanner noise, body weight greater than 500 pounds.
  • Subjects with a baseline level of 25-OH vitamin D \<15 ng/ml will be excluded from the trial. The subject's physician will be notified, and the subject will be referred to their primary care physician.
  • Any significant abnormalities that are considered a risk for utilizing weight management therapies.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment/intervention group

    Treatment with Tirzepatide for 5 months and lifestyle toolkit.

    Drug: Tirzepatide

  • Placebo comparator
    Control/Placebo

    Treatment with Tirzepatide for 5 months with regular diet and exercise.

    Behavioral: Lifestyle toolkit

Interventions

  • GLP-1 based treatment for obesity

  • BehavioralLifestyle toolkit

    2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.

06

What researchers measure

Primary outcomes

  1. Changes in fat free mass (FFM) using DXA imaging. FFM equals all body composition that is not fat mass. This includes bone, skeletal muscle, organs, water and all connective tissues. The unit of measurement is in kilograms (kg) at baseline, 3 and 6 mo.

    DXA (Dual energy Xray absorptiometry)

    Time frame: Baseline and time 3, and 6 months.

Secondary outcomes

  1. MRI (thigh) without contrast

    To assess for muscle quality (% of skeletal muscle to intermuscular fat)

    Time frame: Month 1 (baseline), month 3, month 6 (final visit)

  2. Osteocalcin

    Blood draw, metabolism biomarker

    Time frame: Month 1 (baseline), month 3, month 6 (final visit)

  3. Irisin

    Blood draw, bone health biomarker

    Time frame: Month 1 (baseline), month 3, month 6 (final visit)

  4. Procollagen 1 N-terminal peptide (P1NP)

    Blood draw, bone health biomarker

    Time frame: Month 1 (baseline), month 3, and month 6 (final visit)

  5. C-Terminal Telopeptide of type I collagen (CTX-1)

    Blood draw, bone health biomarker

    Time frame: Month 1 (baseline), month 3, month 6 (final visit)

  6. Insulin-like Growth Factor 1 (IGF-1)

    Blood draw, bone health biomarker

    Time frame: Month 1 (baseline), month 3, month 6 (final visit)

07

Study locations

1 of 2 sites recruiting
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
    Active, not recruiting

    Not enrolling at this site.

  • MaineHealth Center for Clinical and Translational Science
    Scarborough, Maine 04074, United States
    Recruiting
08

References and documents

Publications

  • Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism. 2000 Apr;49(4):467-72. doi: 10.1016/s0026-0495(00)80010-4. PubMed 10778870 ↗
  • Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, Svane MS, Bandholm T, Bojsen-Moller KN, Blond MB, Jensen JB, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198. PubMed 33951361 ↗
  • Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PubMed 35658024 ↗
  • Dubin RL, Heymsfield SB, Ravussin E, Greenway FL. Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps. Diabetes Obes Metab. 2024 Dec;26(12):5503-5518. doi: 10.1111/dom.15913. Epub 2024 Sep 30. PubMed 39344838 ↗

Individual participant data

Plan to share: Yes — Sharing plan of data will be completed by primary study team by 12/01/25. All details will be provided by PI and study team.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data available 2-3 months after study completion date.

Access criteria: Requests for data sharing can be made to study PI (Dubin). The investigators will provide available data using the available resources at the study center.

Data sharing details ↗ · pbrc.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 15 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 4, 2025
StartActual
Oct 9, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
May 1, 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154719
Responsible party
Adithya Hari (Principle Investigator, Pennington Biomedical Research Center) — Principal investigator
First posted
Sep 4, 2025
Start date
Oct 9, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Adithya Hari, MD
Contact
Adithya.Hari@pbrc.edu
225-763-2966
Yanna X Alesafis de Koter, MPH
Contact
yanna.dekoter@pbrc.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion